Evidence map›Paper›PMID 38578805›Full record

ArticlePLoS computational biology2024

A probabilistic knowledge graph for target identification.

Chang Liu, Kaimin Xiao, Cuinan Yu, Yipin Lei, Kangbo Lyu, Tingzhong Tian, Dan Zhao, Fengfeng Zhou, Haidong Tang, Jianyang Zeng

Abstract read
In one paragraph

Article in PLoS computational biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Artemis: Harnessing Knowledge Graphs for Next-Generation Drug Target Prioritization.Computational and structural biotechnology journal · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chang LiuInstitute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.ORCID 0000-0002-7770-7034
Kaimin XiaoSchool of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
Cuinan YuMachine Learning Department, Silexon AI Technology Co., Ltd., Nanjing, Jiangsu Province, China.
Yipin LeiInstitute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.
Kangbo LyuInstitute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.
Tingzhong TianInstitute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.ORCID 0000-0003-4899-0632
Dan ZhaoInstitute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.
Fengfeng ZhouKey Laboratory of Symbolic Computation and Knowledge Engineering of Ministry of Education, College of Computer Science and Technology, Jilin University, Changchun, Jilin Province, China.
Haidong TangSchool of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
Jianyang ZengSchool of Engineering, Westlake University, Hangzhou, China.ORCID 0000-0003-0950-7716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early identification of safe and efficacious disease targets is crucial to alleviating the tremendous cost of drug discovery projects. However, existing experimental methods for identifying new targets are generally labor-intensive and failure-prone. On the other hand, computational approaches, especially machine learning-based frameworks, have shown remarkable application potential in drug discovery. In this work, we propose Progeni, a novel machine learning-based framework for target identification. In addition to fully exploiting the known heterogeneous biological networks from various sources, Progeni integrates literature evidence about the relations between biological entities to construct a probabilistic knowledge graph. Graph neural networks are then employed in Progeni to learn the feature embeddings of biological entities to facilitate the identification of biologically relevant target candidates. A comprehensive evaluation of Progeni demonstrated its superior predictive power over the baseline methods on the target identification task. In addition, our extensive tests showed that Progeni exhibited high robustness to the negative effect of exposure bias, a common phenomenon in recommendation systems, and effectively identified new targets that can be strongly supported by the literature. Moreover, our wet lab experiments successfully validated the biological significance of the top target candidates predicted by Progeni for melanoma and colorectal cancer. All these results suggested that Progeni can identify biologically effective targets and thus provide a powerful and useful tool for advancing the drug discovery process.

Indexed as

Computational BiologyDrug DiscoveryMachine LearningNeural Networks, ComputerAlgorithmsColorectal NeoplasmsHumansMelanomaProbability

Identifiers

PMID38578805
PMCPMC11034645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.